CapsoVision Inc. Announces FDA Enforcement Discretion for At-Home Capsule Endoscopy Administration of CapsoCam Plus during COVID-19
Publication/Creation DateSeptember 23 2020
DescriptionCapsoVision, an innovator in the gastroenterology diagnostics market, today announced that the U.S Food & Drug Administration (FDA) will apply enforcement discretion which allows at-home administration of the CapsoCam Plus small bowel capsule endoscope during the COVID-19 pandemic for patients who are determined eligible for at-home administration. The labeling addendum permits a fully remote capsule endoscopy procedure for eligible patients, eliminating the need for in-person interaction between clinic staff and patient.
Date archivedOctober 3 2021
Last editedOctober 3 2021
How to cite this entry
CapsoVision, Inc.. (September 23 2020). "CapsoVision Inc. Announces FDA Enforcement Discretion for At-Home Capsule Endoscopy Administration of CapsoCam Plus during COVID-19". PRNewswire. Fabric of Digital Life. https://fabricofdigitallife.com/Detail/objects/5459